Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors

Business Wire September 27, 2021

ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Business Wire September 23, 2021

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

Business Wire September 13, 2021

ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference

Business Wire September 9, 2021

ADC Therapeutics Announces Medical Leadership Transition

Business Wire September 3, 2021

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

Business Wire August 26, 2021

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

Business Wire August 3, 2021

ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

Business Wire July 28, 2021

ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma

Business Wire June 22, 2021

ADC Therapeutics Presents Updated ZYNLONTA(TM) (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

Business Wire June 18, 2021

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

Business Wire June 11, 2021

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

Business Wire June 9, 2021

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

Business Wire June 4, 2021

ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

Business Wire May 26, 2021

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA(TM) (Loncastuximab Tesirine-Lpyl)

GlobeNewswire May 25, 2021

ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

Business Wire May 19, 2021

ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield

Business Wire May 17, 2021

ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

Business Wire May 12, 2021

ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

Business Wire May 6, 2021